Currently, several mechanisms have been proposed to mediate the acquired GEM resistance in pancreatic cancer patients, including the reduced expression of nucleoside transporter [3,4], the alterations of nucleotide metabolism enzymes [5,6], and an increased drug efflux by ABC-transporters [7,8,9]. The gene discussed is ABCG2; the disease is pancreatic neoplasm.